CROX vs CRSP: How Crocs and CRISPR Therapeutics AG Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CROX and CRSP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CROX and CRSP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Crocs, Inc. designs and sells casual footwear under two brands. The Crocs Brand centers on its signature molded clog made from a proprietary closed-cell resin the company calls Croslite, extended through sandals, sneakers, and the Jibbitz charms that let buyers personalize their shoes. In 2022 Crocs acquired HEYDUDE, a lightweight casual-shoe brand, to add a second growth engine. The company sells through wholesale partners and a growing direct-to-consumer channel that includes its own websites and stores, and it markets heavily through collaborations and celebrity tie-ins. Crocs is known for operating margins well above most footwear peers, driven by a simple core product, strong pricing, and relatively low marketing spend versus sales.

Full CROX guide

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

Full CRSP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CROX drivers: High-margin core Crocs Brand; Cash generation and share buybacks.
• CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest risk is that Crocs depends heavily on one iconic product, so a shift in fashion or a fading of the clog trend could hurt demand quickly, and single-product concentration makes the stock sensitive to sentiment about the brand's staying power. For CRSP, the commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CROX if you believe its drivers more; CRSP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CROX and CRSP guides.

CROX. These figures are approximate, tied to the asOf date, and change with new filings and market moves, so verify live numbers before acting. A low forward P/E on Crocs reflects skepticism about whether current profitability lasts, especially given the HEYDUDE drag and single-product concentration, so the cheap multiple is a judgment about risk rather than a guarantee of value. Guidance can be revised, and tariff or demand shifts can move the numbers meaningfully.

CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based valuation multiples like P/E are negative and not analytically useful. The company is better evaluated on its cash runway, the pace of Casgevy's commercial adoption, and the risk-adjusted value of its pipeline. Enterprise value of roughly $2.8 billion (market cap less net cash) reflects the market pricing in significant execution uncertainty around both the Casgevy ramp and the broader pipeline, while a wide spread exists between bearish analyst targets near $33 and optimistic targets above $80.

Headline figures (approximate, Jul 2026): CROX shows revenue (annual) roughly $4 billion range across both brands, q1 2026 revenue ~$921 million, down modestly year over year, fy2026 adjusted eps guidance company guided to roughly $13.20 to $13.75 (adjusted, subject to revision), operating margin unusually high for footwear, historically in the mid-20s percent range enterprise-wide; CRSP shows revenue (full year 2025, product only) ~$3.5 million, revenue (full year 2024) ~$37.3 million (primarily collaboration revenue), net loss (ttm through q3 2025) ~$488 million, operating loss (full year 2025) ~$665 million.

CROX and CRSP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CROX and CRSP exposure against your real portfolio. It is not an investment adviser.